Use of imiquimod cream 5% in the treatment of localized morphea

Journal of Cutaneous Medicine and Surgery

Volumn 8, Issue 3, 2004, Pages 166-169

  Man, Jeremy ^a   Dytoc, Marlene T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; ANAMNESIS; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; FEMALE; HUMAN; IMMUNOFLUORESCENCE; LABORATORY TEST; MORPHEA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BIOPSY;

ADULT; AMINOQUINOLINES; DOSAGE FORMS; FEMALE; HUMANS; INTERFERON INDUCERS; SCLERODERMA, LOCALIZED;

EID: 11244280899     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-003-0112-2     Document Type: Article

References (18)

1. Simms RW, Korn JH.. Cytokine directed therapy in scleroderma: rationale, current status, and the future. Curr Opin Rheumatol 2002; 146:717-722.
2. Naiki Y, Maeda Y, Matsuo K, et al. Involvement of TGF-ss signal for peritoneal sclerosing in continuous ambulatory peritoneal dialysis. J Nephrol 2003; 161:95-102.
3. Ihn H.. Pathogenesis of fibrosis: role of TGF-[beta] and CTGF. Curr Opin Rheumatol 2002; 146:681-685.
4. Sehgal VN, Srivastava G, Aggarwal AK, et al. Localized scleroderma/morphea. Int J Dermatol 2002; 418:467-475.
5. Kawakami T, Soma Y, Baba T, et al. Immunohistochemical analysis of transforming growth factor beta 3 expression in solitary morphoea profunda with histological membranocystic changes. Br J Dermatol 2002; 1461:171-173.
6. Kubo M, Ihn H, Yamane K, et al. Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J Rheumatol 2002; 2912:2558-2564.
7. Ihn H. The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma. Arch Immunol Ther Exp (Warsz) 2002; 505:323-331.
8. Connolly MK. Scleroderma. Dermatol Ther 2001; 14:81-94.
9. Karrer S, Abels C, Landthaler M, et al. Topical photodynamic therapy for localized scleroderma. Acta Derm Venereol 2000; 801:26-27.
10. Uziel Y, Feldman BM, Krafchik BR, et al. Methotrexate and corticosteroids therapy for pediatric localized scleroderma. J Pediatr 2000; 1361:91-95.
11. Caca-Biljanovska NG, Vlckova-Laskoska MT, Dervendi DV, et al. Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol 1999; 455:299-304.
12. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002; 1381:99-105.
13. Eedy DJ. Imiquimod: a potential role in dermatology? Br J Dermatol 2002; 1471:1-6.
14. Dahl MV. Imiquimod: a cytokine inducer. J Am Acad Dermatol 2002; 474 Suppl:S205-S208.
15. Pearson GW, Langley RGB. Topical imiquimod. J Dermatol Treat 2001; 121:37-40.
16. Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999; 1911:10-19.
17. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002; 1381:99-105.
18. Selman M. From anti-inflammatory drugs through antifibrotic agents to lung transplantation: a long road of research, clinical attempts, and failures in the treatment of idiopathic pulmonary fibrosis. Chest 2002; 1223:759-761.